Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SHARE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMed2000

Are morphological effects distinguishable from the effects of shared meaning and shared form?

Effects of orthographically and semantically related primes were compared with morphologically related primes in an immediate (Experiment 1) and a long-term (Experiment 2) lexical decision task. Morphological relatedness produced facilitation across a range of prime durations (32-300 ms) as well as when items intervened between prime and target, and its magnitude increased with prime duration. Semantic facilitation and orthographic inhibition arose only in the immediate priming task. Moreover, morphological effects were significantly greater than the sum of semantic and orthographic effects at a stimulus onset asynchrony of 300 ms but were not reliably different at shorter durations. The adequacy of an account that describes morphological relatedness as distinct from the composite effects of semantic and orthographic similarity must account for changes in additivity across prime durations.

Adolescent↗
PubMed1977

Sharing of Ia antigens between species. I. Detection of Ia specificities shared by rats and mice.

A mouse anti-rat xenogeneic antiserum, B10.D2 anti-BN, has been found to react with a subpopulation of lymphoid cells of certain mouse strains. The corresponding alloantiserum, B10.D2 anti-B10.BR, reacted in analogous fashion with lymphoid cells of BN rats. In the case of the cross-reaction on mouse cells, mapping studies indicated that at least part of the reactivity was with the product of gene(s) determined by the I-A subregion of the H-2 complex. Chemical isolation studies with radiolabeled cell surface preparations indicated that the antigens detected in both mouse and rat had mol wt characteristic of Ia antigens (35,000 and 28,000 dalton molecules). Testing of fractionated spleen cell populations revealed that the cross-reactive antigens were expressed predominatly on B cells, but that a subpopulation of T cells were also reactive. Wider strain and species distribution studies are in progress to determine the extent of such Ia cross-reactions between species and to further assess the practical and theoretical importance of such cross-reactions.

Animals↗
PubMed1985

To share or not to share.

We describe our extensive experience in nipple reconstruction on breasts formed by subpectoral implants, latissimus dorsi musculocutaneous flaps, or rectus abdominis musculocutaneous flaps.

Breast↗
PubMed1979

Sharing Ia antigens between species. III. Ia specificities shared between mice and human beings.

Certain mouse alloantisera have been found to detect immunologic cross-reactions between human and murine Ia antigens. Almost every anti-Iaa, -Iak and -Iad serum tested exhibited such cross-reactions. Sera prepared against the products of limited segments of the mouse I region and tested on human B cells revealed that anti-I-E/Ck cross-reactions were more readily detectable than anti-I-A, B, Jk cross-reactions. Most of the mouse alloantisera were cytotoxic to bells from almost every individual tested, although a few sera exhibited more restricted patterns of lysis, permitting limited segregation analyses. The cytotoxicity of these mouse alloantisera in family studies was consistent with HLA linkage of the genes responsible for the cross-reacting Ia determinants. Immunochemical analysis on radiolabelled detergent lysates of human lymphocytes indicated that the sera reacted with molecules of 34,000 and 28,000 daltons. Thus, by cellular distribution, HLA association, and immunochemical criteria, these mouse alloantisera detect human Ia antigens. These cross-reactive sera should be of practical value for the detection of human Ia antigens and may also have theoretical implications for the evolution of genes coding for Ia antigens.

Animals↗
PubMed2004

Pharmaceutical care for elderly patients shared between community pharmacists and general practitioners: a randomised evaluation. RESPECT (Randomised Evaluation of Shared Prescribing for Elderly people in the Community over Time) [ISRCTN16932128].

BACKGROUND: This trial aims to investigate the effectiveness and cost implications of 'pharmaceutical care' provided by community pharmacists to elderly patients in the community. As the UK government has proposed that by 2004 pharmaceutical care services should extend nationwide, this provides an opportunity to evaluate the effect of pharmaceutical care for the elderly. DESIGN: The trial design is a randomised multiple interrupted time series. We aim to recruit 700 patients from about 20 general practices, each associated with about three community pharmacies, from each of the five Primary Care Trusts in North and East Yorkshire. We shall randomise the five resulting groups of practices, pharmacies and patients to begin pharmaceutical care in five successive phases. All five will act as controls until they receive the intervention in a random sequence. Until they receive training community pharmacists will provide their usual dispensing services and so act as controls. The community pharmacists and general practitioners will receive training in pharmaceutical care for the elderly. Once trained, community pharmacists will meet recruited patients, either in their pharmacies (in a consultation room or dispensary to preserve confidentiality) or at home. They will identify drug-related issues/problems, and design a pharmaceutical care plan in conjunction with both the GP and the patient. They will implement, monitor, and update this plan monthly. The primary outcome measure is the 'Medication Appropriateness Index'. Secondary measures include adverse events, quality of life, and patient knowledge and compliance. We shall also investigate the cost of pharmaceutical care to the NHS, to patients and to society as a whole.

Aged↗